Evaluation of vaccines against flu — Competitive Intelligence Brief

Evaluation of vaccines against flu (Evaluation of vaccines against flu) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Immunology.

marketed vaccine Immunology Biologic

Target snapshot

Evaluation of vaccines against flu (Evaluation of vaccines against flu) — Assistance Publique - Hôpitaux de Paris. Flu vaccines stimulate the immune system to produce antibodies and cellular immunity against influenza virus strains, providing protection against infection and severe disease.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Evaluation of vaccines against flu TARGET	Evaluation of vaccines against flu	Assistance Publique - Hôpitaux de Paris	marketed	vaccine
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
Prevenar 13 + Pneumovax 23	Prevenar 13 + Pneumovax 23	Poitiers University Hospital	marketed	Pneumococcal vaccine combination
Inactivated SARS-CoV-2 Vaccine (Vero cell）	Inactivated SARS-CoV-2 Vaccine (Vero cell）	Sinovac Research and Development Co., Ltd.	marketed	inactivated viral vaccine	SARS-CoV-2 spike protein and other viral antigens
Pandemic influenza A/H1N1 vaccine	Pandemic influenza A/H1N1 vaccine	Sinovac Biotech Co., Ltd	marketed	inactivated influenza vaccine
Meningococcal A+C vaccine	Meningococcal A+C vaccine	Sanofi Pasteur, a Sanofi Company	marketed	Polysaccharide conjugate vaccine	Neisseria meningitidis serogroups A and C capsular polysaccharides

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
• 2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (vaccine class)

1. Pfizer · 20 drugs in this class
2. Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
3. GlaxoSmithKline · 12 drugs in this class
4. Merck Sharp & Dohme LLC · 12 drugs in this class
5. Centers for Disease Control and Prevention · 9 drugs in this class
6. Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
7. Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
8. Beijing Center for Disease Control and Prevention · 6 drugs in this class
9. International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
10. Sinovac Biotech Co., Ltd · 4 drugs in this class